A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and Allina Health. Barostim is the world’s first FDA-approved neuromodulation heart failure device, which works by stimulating baroreceptors, natural sensors located in the wall of the carotid artery.
The facility for less-complicated heart procedures continues a partnership to develop free-standing surgery centers with a division of Minnetonka-based UnitedHealth Group.